|
| 產(chǎn)地 | 進(jìn)口、國產(chǎn) |
| 品牌 | 上海莼試 |
| 保存條件 | Store at -20 °C |
| 貨號 | CS10059 |
| 應(yīng)用范圍 | WB=1:100-500 ELISA=1:500-1000 IHC-P=1:100-500 IHC-F=1:100-500 ICC=1:100-500 IF=1:100-500 |
| CAS編號 | |
| 抗體名 | Anti-OPA1 |
| 克隆性 | |
| 靶點(diǎn) | 詳見說明書 |
| 適應(yīng)物種 | 詳見說明書 |
| 形態(tài) | 詳見說明書 |
| 宿主 | 詳見說明書 |
| 亞型 | IgG |
| 標(biāo)識物 | 詳見說明書 |
| 濃度 | 1mg/1ml% |
| 免疫原 | KLH conjugated synthetic peptide derived from human OPA1 |
產(chǎn)品訂購信息：
英文名稱 Anti-OPA1
中文名稱 相關(guān)蛋白1抗體品牌
別 名 Dynamin like 120 kDa protein; Dynamin like 120 kDa protein, mitochondrial; Dynamin-like 120 kDa protein; Dynamin-like 120 kDa protein, form S1; FLJ12460; Juvenile kjer type optic atrophy; Juvenile kjer-type optic atrophy; KIAA0567; KJER type; Large GTP binding protein; largeG; MGM1; Mitochondrial dynamin like 120 kDa protein; Mitochondrial dynamin like GTPase; NPG; NTG; OAK; OPA 1; OPA1; OPA1 gene; OPA1_HUMAN; Optic atrophy 1 (autosomal dominant); OPTIC ATROPHY 1; Optic atrophy 1 gene protein; Optic atrophy 1 homolog (human); Optic atrophy protein 1; Optic atrophy protein 1 homolog.
濃 度 1mg/1ml
規(guī) 格 0.2ml/200μg
抗體來源 Rabbit
克隆類型 polyclonal
交叉反應(yīng) Human, Mouse, Rat, Dog, Pig, Cow, Horse, Rabbit, Sheep
產(chǎn)品類型 一抗
研究領(lǐng)域 心 細(xì)胞生物 神經(jīng)生物學(xué)
蛋白分子量 predicted molecular weight: 111kDa
性 狀 Lyophilized or Liquid
免 疫 原 KLH conjugated synthetic peptide derived from human OPA1
亞 型 IgG
純化方法 affinity purified by Protein A
儲 存 液 Preservative: 15mM Sodium Azide, Constituents: 1% BSA, 0.01M PBS, pH 7.4
相關(guān)蛋白1抗體品牌 產(chǎn)品應(yīng)用 WB=1:100-500 ELISA=1:500-1000 IHC-P=1:100-500 IHC-F=1:100-500 ICC=1:100-500 IF=1:100-500
（石蠟切片需做抗原修復(fù)）
not yet tested in other applications.
optimal dilutions/concentrations should be determined by the end user.
保存條件 Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C.
Important Note This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications.
產(chǎn)品介紹 OPA1 is a 120kDa protein belonging to the dynamin family. The OPA1 gene has been localized to 3q29. The gene is targeted to mitochondria and is involved in mitochondrial biogenesis. Defects in OPA1 are a cause of optic atrophy type 1. OPA1 is mostly expressed in retina but can also be expressed in brain, testis, heart and skeletal muscle.
Function : Dynamin-related GTPase required for mitochondrial fusion and regulation of apoptosis. May form a diffusion barrier for proteins stored in mitochondrial cristae. Proteolytic processing in response to intrinsic apoptotic signals may lead to disassembly of OPA1 oligomers and release of the caspase activator cytochrome C (CYCS) into the mitochondrial intermembrane space.
Subcellular Location : Mitochondrion inner membrane. Mitochondrion intermembrane space.
Tissue Specificity : Highly expressed in retina. Also expressed in brain, testis, heart and skeletal muscle. Isoform 1 expressed in retina, skeletal muscle, heart, lung, ovary, colon, thyroid gland, leukocytes and fetal brain. Isoform 2 expressed in colon, liver, kidney, thyroid gland and leukocytes. Low levels of all isoforms expressed in a variety of tissues.
Post-translational modifications : PARL-dependent proteolytic processing releases an antiapoptotic soluble form not required for mitochondrial fusion.
DISEASE : Defects in OPA1 are a cause of optic atrophy type 1 (OPA1) [MIM:165500]. OPA1 is a dominantly inherited optic neuropathy occurring in 1 in 50,000 individuals that features progressive loss in visual acuity leading, in many cases, to legal blindness.
Defects in OPA1 are the cause of optic atrophy 1 with deafness (OPA1D) [MIM:125250]. Some individuals with mutations in OPA1 manifest also ophthalmoplegia and myopathy.
Similarity : Belongs to the dynamin family.
Database links : UniProtKB/Swiss-Prot: O60313.3
Collagen I 小鼠I型膠原Multi-class antibodies規(guī)格： 48T
Anti-DUSP1/MKP-1 原活化蛋白激酶磷酸酶-1抗體Multi-class antibodies規(guī)格： 0.2ml
Rhesus antibody Rh MTBP/MDM2BP 雙微體2癌基因結(jié)合蛋白抗體 規(guī)格 0.2ml
TPS(Human Total protein S) ELISA Kit 人總蛋白S 96T
SOX30 英文名稱： 轉(zhuǎn)錄因子SOX30抗體 0.1ml
CD14 英文名稱： 內(nèi)毒素受體抗體 0.1ml
Anti-DUSP1/MKP-1 原活化蛋白激酶磷酸酶-1抗體Multi-class antibodies規(guī)格： 0.2ml
UPAR 人凝血酶受體Multi-class antibodies規(guī)格： 48T
Anti-Connexin-32 間隙連接蛋白32抗體Multi-class antibodies規(guī)格： 0.1ml
Rhesus antibody Rh Nicastrin 蛋白APH2抗體 規(guī)格 0.1ml
Human Ig-like transcripts Receptor,ILTsR ELISA Kit 人免疫球蛋白樣轉(zhuǎn)錄體受體 96T
TNFRSF5 英文名稱： 壞死因子受體超家族成員5抗體 0.1ml
Claudin 22 英文名稱： 緊密連接蛋白22抗體 0.1ml
Anti-Connexin-32 間隙連接蛋白32抗體Multi-class antibodies規(guī)格： 0.1ml
Adiponectin 脂聯(lián)素(多肽片斷抗原)Multi-class antibodies規(guī)格： 0.5mg
Anti-B7H4 B7-H4抗體Multi-class antibodies規(guī)格： 0.1ml
Rhesus antibody Rh Phospho-Ack1(Tyr859/860) 磷酸化Ack1抗體 規(guī)格 0.1ml
MAP2a,b 濃縮液 0.1ml 進(jìn)口分裝
UBF1 英文名稱： RNA聚合酶I抗體 0.1ml
CHST6 英文名稱： 碳水化合物磺基轉(zhuǎn)移酶6抗體 0.1ml
Anti-B7H4 B7-H4抗體Multi-class antibodies規(guī)格： 0.1ml
VEGFA Protein Human 重組人 / 食蟹猴 VEGF / VEGFA / VEGF165 蛋白
HSC 人細(xì)胞
LAIR2 Others Human 人 LAIR2 / CD306 人細(xì)胞裂解液 (陽性對照)
J82人膀胱移行細(xì)胞癌 J82 human bladder ansitional cell carcinoma MEM培養(yǎng)基(GIBCO)+10%FBS
大額牛肺細(xì)胞;BFR-L1
大鼠*管狀上皮細(xì)胞(RRTEpiC)(5×105) RL95-2, 人子宮內(nèi)膜腺癌細(xì)胞系 Human
CL-0371K7M2 wt(小鼠成骨細(xì)胞)5×106cells/瓶×2
MAPK1 Others Human 人 ERK2 / MAPK1 / MAPK2 桿狀病毒-昆蟲細(xì)胞裂解液 (陽性對照)
人肝竇內(nèi)皮細(xì)胞總RNAHHSEC NA
T-24細(xì)胞，膀胱變移細(xì)胞癌 人肺鱗癌細(xì)胞,SK-MES-1細(xì)胞 UM-UC-3, 人膀胱移行細(xì)胞癌
家貓肺細(xì)胞;FCA-L1
HA Others H1N1 甲型 H1N1 (A/California/04/2009) 血凝素 (Hemagglutinin / HA) 人細(xì)胞裂解液 (陽性對照)
相關(guān)蛋白1抗體品牌 VEGFA Protein Human 重組人 / 食蟹猴 VEGF / VEGFA / VEGF165 蛋白
HSC 人細(xì)胞
LAIR2 Others Human 人 LAIR2 / CD306 人細(xì)胞裂解液 (陽性對照)
J82人膀胱移行細(xì)胞癌 J82 human bladder ansitional cell carcinoma MEM培養(yǎng)基(GIBCO)+10%FBS
大額牛肺細(xì)胞;BFR-L1
大鼠*管狀上皮細(xì)胞(RRTEpiC)(5×105) RL95-2, 人子宮內(nèi)膜腺癌細(xì)胞系 Human
抗體的生物素化標(biāo)記實驗要點(diǎn)：
1. 相關(guān)蛋白1抗體品牌 如在反應(yīng)混合液中有疊氮鈉或游離氨基存在,會抑制標(biāo)記反應(yīng)。因此,蛋白質(zhì)在反應(yīng)前要對 0.1mol/L碳酸氫鈉緩沖液或0.5mol/L硼酸緩沖液充分透析；
2.所用的NHSB及待生物素化蛋白質(zhì)之間的分子比按蛋白質(zhì)表面的ε-氨基的密度會有所不同,選擇不當(dāng)則影響標(biāo)記的效率,應(yīng)先用幾個不同的分子比來篩選最適條件；
3.用NHSB量過量也是不利的,抗原的結(jié)合位點(diǎn)可能因此被封閉,導(dǎo)致抗體失活；
4.由于抗體的氨基不易接近可能造成生物素化不足,此時可加入去污劑如 Triton x-100, Tween20等；
5.當(dāng)游離ε-氨基(賴氨酸殘基的氨基)存在于抗體的抗原結(jié)合位點(diǎn)時,或位于酶的催化位點(diǎn)時,生物素化會降低或損傷抗體蛋白的結(jié)合力或活性；
6.生物素還可能與不同的功能基團(tuán),如羰基、氨基、巰基、異咪唑基及苯酚基,也可與糖基共價結(jié)合；
7.交聯(lián)反應(yīng)后,應(yīng)充分透析,否則,殘余的生物素會對生物素化抗體與親和素的結(jié)合產(chǎn)生競爭作用；
8.在細(xì)胞的熒光標(biāo)記實驗中,中和親和素的本底低,但由于鏈霉親和素含有少量正電荷,故對某些細(xì)胞可導(dǎo)致高本底。
抗體的鑒定：
1）相關(guān)蛋白1抗體品牌 抗體的效價鑒定：不管是用于診斷還是用于,制備抗體的目的都是要求較高效價。不同的抗原制備的抗體,要求的效價不一。鑒定效價的方法很多,包括有試管凝集反應(yīng),瓊脂擴(kuò)散試驗,酶聯(lián)免疫吸附試驗等。常用的抗原所制備的抗體一般都有約成的鑒定效價的方法,以資比較。如制備抗抗體的效價,一般就采用瓊脂擴(kuò)散試驗來鑒定。
2）抗體的特異性鑒定：抗體的特異性是指與相應(yīng)抗原或近似抗原物質(zhì)的識別能力。抗體的特異性高,它的識別能力就強(qiáng)。衡量特異性通常以交叉反應(yīng)率來表示。交叉反應(yīng)率可用競爭抑制試驗測定。以不同濃度抗原和近似抗原分別做競爭抑制曲線,計算各自的結(jié)合率,求出各自在IC50時的濃度,并按公式計算交叉反應(yīng)率。
如果所用抗原濃度IC50濃度為pg/管,而一些近似抗原物質(zhì)的IC50濃度幾乎是無窮大時,表示這一抗血清與其他抗原物質(zhì)的交叉反應(yīng)率近似為0,即該血清的特異性較好。
3）抗體親和力：是指抗體和抗原結(jié)合的牢固程度。親和力的高低是由抗原分子的大小,抗體分子的結(jié)合位點(diǎn)與抗原決定簇之間立體構(gòu)型的合適度決定的。有助于維持抗原抗體復(fù)合物穩(wěn)定的分子間力有氫鍵,疏水鍵,側(cè)鏈相反電荷基因的庫侖力,范德華力和空間斥力。親和力常以親和常數(shù)K表示,K的單位是L/mol?？贵w親和力的測定對抗體的篩選,確定抗體的用途,驗證抗體的均一性等均有重要意義。
|
|
|
|
